Peter Westervelt
#84,287
Most Influential Person Now
American physicist
Peter Westervelt's AcademicInfluence.com Rankings
Download Badge
Physics
Peter Westervelt's Degrees
- PhD Physics Stanford University
Why Is Peter Westervelt Influential?
(Suggest an Edit or Addition)According to Wikipedia, Peter Westervelt was an American physicist, noted for his work in nonlinear acoustics, and Professor Emeritus of Physics at Brown University. Education He received his BS in Physics from MIT in 1947, and his PhD in Physics from MIT in 1951, at which time he joined the Physics Department at Brown University.
Peter Westervelt's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Recurring mutations found by sequencing an acute myeloid leukemia genome. (2009) (2200)
- Clonal evolution in relapsed acute myeloid leukemia revealed by whole genome sequencing (2011) (1935)
- Oncogenic Signaling Pathways in The Cancer Genome Atlas (2018) (1646)
- The Origin and Evolution of Mutations in Acute Myeloid Leukemia (2012) (1420)
- DNA sequencing of a cytogenetically normal acute myeloid leukemia genome (2008) (1365)
- Comprehensive Characterization of Cancer Driver Genes and Mutations (2018) (1360)
- DNMT3A mutations in acute myeloid leukemia. (2010) (782)
- Clonal architecture of secondary acute myeloid leukemia. (2012) (747)
- Peripheral-blood stem cells versus bone marrow from unrelated donors. (2012) (698)
- TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. (2016) (582)
- RECURRENT MUTATIONS IN THE U2AF1 SPLICING FACTOR IN MYELODYSPLASTIC SYNDROMES (2011) (530)
- Recurrent DNMT3A Mutations in Patients with Myelodysplastic Syndromes (2011) (508)
- Pathogenic Germline Variants in 10,389 Adult Cancers (2018) (501)
- Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients (2018) (471)
- The Role of TP53 Mutations in the Origin and Evolution of Therapy-Related AML (2014) (442)
- Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. (2008) (325)
- Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. (2008) (302)
- Macrophage tropism determinants of human immunodeficiency virus type 1 in vivo (1992) (293)
- Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia. (2015) (285)
- NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes. (2011) (277)
- Clonal diversity of recurrently mutated genes in myelodysplastic syndromes (2013) (269)
- Identification of a determinant within the human immunodeficiency virus 1 surface envelope glycoprotein critical for productive infection of primary monocytes. (1991) (268)
- Use of whole-genome sequencing to diagnose a cryptic fusion oncogene. (2011) (267)
- Acquired copy number alterations in adult acute myeloid leukemia genomes (2009) (258)
- Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. (2001) (245)
- First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. (2018) (244)
- Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. (2017) (236)
- Immune Escape of Relapsed AML Cells after Allogeneic Transplantation (2018) (235)
- A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. (2012) (233)
- Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. (2008) (205)
- Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia. (2015) (197)
- Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context (2018) (188)
- Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation. (2017) (177)
- CpG Island Hypermethylation Mediated by DNMT3A Is a Consequence of AML Progression (2017) (155)
- DNMT 3 A mutations in acute myeloid leukemia (2016) (151)
- High-penetrance mouse model of acute promyelocytic leukemia with very low levels of PML-RARalpha expression. (2003) (144)
- Myeloid growth factors. (2013) (141)
- Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential (2018) (135)
- Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome. (2015) (128)
- Acquired, nonrandom chromosomal abnormalities associated with the development of acute promyelocytic leukemia in transgenic mice. (2000) (119)
- Dual regulation of silent and productive infection in monocytes by distinct human immunodeficiency virus type 1 determinants (1992) (119)
- Clonal Architecture of Secondary Acute Myeloid Leukemia Defined by Single-Cell Sequencing (2014) (118)
- A bcr-3 isoform of RARα-PML potentiates the development of PML-RARα-driven acute promyelocytic leukemia (1999) (117)
- Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin (2001) (110)
- Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia (2013) (109)
- Severe Cytokine-Release Syndrome after T Cell-Replete Peripheral Blood Haploidentical Donor Transplantation Is Associated with Poor Survival and Anti-IL-6 Therapy Is Safe and Well Tolerated. (2016) (108)
- A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia. (2011) (104)
- Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. (2017) (103)
- Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML. (2016) (92)
- Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia. (2007) (92)
- Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation. (2011) (90)
- Comparison of Patient-Reported Outcomes in 5-Year Survivors Who Received Bone Marrow vs Peripheral Blood Unrelated Donor Transplantation: Long-term Follow-up of a Randomized Clinical Trial. (2016) (88)
- Genome Sequencing as an Alternative to Cytogenetic Analysis in Myeloid Cancers. (2021) (86)
- Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial (2018) (86)
- Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802. (2014) (82)
- Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimen. (2014) (81)
- Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (Valspodar), in refractory malignancies. (2000) (81)
- An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes (2014) (80)
- Dynamic Changes in the Clonal Structure of MDS and AML in Response to Epigenetic Therapy (2015) (78)
- A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease. (2005) (70)
- Epidemiology of infections following haploidentical peripheral blood hematopoietic cell transplantation (2016) (68)
- Recognizing and managing the expanded risk of tumor lysis syndrome in hematologic and solid malignancies (2012) (65)
- NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020. (2020) (65)
- Seed versus soil: the importance of the target cell for transgenic models of human leukemias. (1999) (60)
- Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft. (2017) (58)
- Mutation Clearance after Transplantation for Myelodysplastic Syndrome (2018) (57)
- Limited sequence heterogeneity among biologically distinct human immunodeficiency virus type 1 isolates from individuals involved in a clustered infectious outbreak. (1990) (57)
- Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901. (2011) (57)
- Use of Cytomegalovirus Intravenous Immune Globulin for the Adjunctive Treatment of Cytomegalovirus in Hematopoietic Stem Cell Transplant Recipients (2010) (56)
- A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. (2017) (53)
- Multidimensional analyses of donor memory-like NK cells reveal new associations with response after adoptive immunotherapy for leukemia. (2020) (47)
- Cytomegalovirus viremia, disease, and impact on relapse in T-cell replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide (2016) (47)
- TP 53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes (2016) (47)
- Comparison of Outcomes after Peripheral Blood Haploidentical versus Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia: A Retrospective Single-Center Review. (2016) (46)
- Mouse models of acute promyelocytic leukemia (2001) (45)
- Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: A phase I study (2011) (43)
- Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G‐CSF (2009) (43)
- Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2:2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) (2018) (43)
- Adaptive immunity cooperates with liposomal all-trans-retinoic acid (ATRA) to facilitate long-term molecular remissions in mice with acute promyelocytic leukemia (2002) (43)
- Comprehensive genomic analysis reveals FLT3 activation and a therapeutic strategy for a patient with relapsed adult B-lymphoblastic leukemia. (2016) (42)
- Subclones dominate at MDS progression following allogeneic hematopoietic cell transplant. (2018) (42)
- A phase II study of 5‐day intravenous azacitidine in patients with myelodysplastic syndromes (2009) (42)
- A phase 1/2 study of chemosensitization with plerixafor plus G-CSF in relapsed or refractory acute myeloid leukemia (2017) (41)
- A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia. (2018) (41)
- A phase 1 / 2 study of chemosensitization with the CXCR 4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia (2012) (40)
- A phase 1 study of concomitant high-dose lenalidomide and 5-azacitidine induction in the treatment of AML (2013) (38)
- Myelodysplastic syndromes, version 2.2015 featured updates to the NCCN guidelines (2015) (37)
- A bcr-3 isoform of RARalpha-PML potentiates the development of PML-RARalpha-driven acute promyelocytic leukemia. (1999) (36)
- Low incidence of transplantation-related acute complications in patients with chronic myeloid leukemia undergoing allogeneic stem cell transplantation with a low-dose (550 cGy) total body irradiation conditioning regimen. (2001) (36)
- Comparative Evaluation of Single Fixed Dosing and Weight‐Based Dosing of Rasburicase for Tumor Lysis Syndrome (2013) (36)
- Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome (2021) (36)
- Structure—function relationships of the HIV‐1 envelope V3 loop tropism determinant: evidence for two distinct conformations (1993) (36)
- Haploidentical Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide and Peripheral Blood Stem Cell Grafts in Older Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome. (2017) (35)
- T Cell-Replete Peripheral Blood Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide Results in Outcomes Similar to Transplantation from Traditionally Matched Donors in Active Disease Acute Myeloid Leukemia. (2017) (35)
- Considerations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 Pandemic. (2020) (33)
- Myeloid growth factors. Clinical practice guidelines in oncology. (2007) (32)
- Post-transplant high-dose cyclophosphamide after HLA-matched vs haploidentical hematopoietic cell transplantation for AML (2016) (32)
- Myeloid growth factors. (2009) (32)
- Fresh or Cryopreserved CD34+-Selected Mobilized Peripheral Blood Stem and Progenitor Cells for the Treatment of Poor Graft Function after Allogeneic Hematopoietic Cell Transplantation. (2017) (31)
- Myelodysplastic syndromes, version 2.2015. (2015) (31)
- Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML (2014) (31)
- Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation. (2016) (30)
- Adverse side-effects associated with G-CSF in patients with chronic myeloid leukemia undergoing allogeneic peripheral blood stem cell transplantation (2000) (30)
- Low-dose (550 cGy), single-exposure total body irradiation and cyclophosphamide: consistent, durable engraftment of related-donor peripheral blood stem cells with low treatment-related mortality and fatal organ toxicity. (2002) (30)
- Myelodysplastic syndromes: clinical practice guidelines in oncology. (2013) (28)
- Chemotherapy versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplant. (2016) (26)
- Resolution of psoriasis after allogeneic bone marrow transplantation for chronic myelogenous leukemia: late complications of therapy (2000) (25)
- Identification of HIV1 determinants for T lymphoid cell line infection. (1993) (25)
- Role of HIV-1 envelope V3 loop cleavage in cell tropism. (1993) (25)
- Haploidentical transplantation using G-CSF-mobilized T-cell replete PBSCs and post-transplantation CY after non-myeloablative conditioning is safe and is associated with favorable outcomes (2014) (25)
- Allo-SCT conditioning for myelodysplastic syndrome and acute myeloid leukemia with clofarabine, cytarabine and ATG (2009) (25)
- Silybum marianum (milk thistle) in the management and prevention of hepatotoxicity in a patient undergoing reinduction therapy for acute myelogenous leukemia (2012) (24)
- Pathologic, Cytogenetic and Molecular Assessment of Acute Promyelocytic Leukemia Patients Treated with Arsenic Trioxide (As2O3) (2000) (23)
- Immune hemolysis involving non-ABO/RhD alloantibodies following hematopoietic stem cell transplantation (2001) (23)
- Caspase-9 is required for normal hematopoietic development and protection from alkylator-induced DNA damage in mice. (2014) (23)
- NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022. (2022) (22)
- Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy. (2021) (22)
- The isolation and identification of 3,4-dihydroxybenzoic acid formed by nitrogen-fixing Azomonas macrocytogenes (1985) (22)
- Phase 2 Study of MLN8237, An Investigational Aurora A Kinase (AAK) Inhibitor In Patients with Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndromes (MDS) (2010) (20)
- Oral valganciclovir versus ganciclovir as delayed pre‐emptive therapy for patients after allogeneic hematopoietic stem cell transplant: a pilot trial (04‐0274) and review of the literature (2012) (20)
- Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10‐day decitabine regimen (2017) (19)
- Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy. (2017) (18)
- Results of a Prospective Randomized, Open-Label, Noninferiority Study of Tbo-Filgrastim (Granix) versus Filgrastim (Neupogen) in Combination with Plerixafor for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma. (2017) (18)
- A common founding clone with TP53 and PTEN mutations gives rise to a concurrent germ cell tumor and acute megakaryoblastic leukemia (2016) (17)
- Donor-lymphocyte infusion following haploidentical hematopoietic cell transplantation with peripheral blood stem cell grafts and PTCy (2017) (17)
- A phase I study of carfilzomib for relapsed or refractory acute myeloid and acute lymphoblastic leukemia (2014) (17)
- Assessment of an Alternative Meropenem Dosing Strategy Compared with Imipenem‐Cilastatin or Traditional Meropenem Dosing After Cefepime Failure or Intolerance in Adults with Neutropenic Fever (2009) (17)
- A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantation (2017) (16)
- Response and toxicity associated with dose escalation of arsenic trioxide in the treatment of resistant acute promyelocytic leukemia (1997) (16)
- Recurrent DNMT3A Mutations In Patients with Myelodysplastic Syndrome (2010) (16)
- Effect of Antihuman T Lymphocyte Globulin on Immune Recovery after Myeloablative Allogeneic Stem Cell Transplantation with Matched Unrelated Donors: Analysis of Immune Reconstitution in a Double-Blind Randomized Controlled Trial. (2018) (16)
- The Role Of Early TP53 Mutations On The Evolution Of Therapy-Related AML (2013) (15)
- High-dose cyclophosphamide, BCNU, and VP-16 (CBV) conditioning before allogeneic stem cell transplantation for patients with non-Hodgkin's lymphoma (2003) (15)
- A Prospective Randomized Double Blind Phase 3 Clinical Trial of Anti- T Lymphocyte Globulin (ATLG) to Assess Impact on Chronic Graft-Versus-Host Disease (cGVHD) Free Survival in Patients Undergoing HLA Matched Unrelated Myeloablative Hematopoietic Cell Transplantation (HCT) (2016) (15)
- Mobilization and Chemosensitization of AML with the CXCR4 Antagonist Plerixafor (AMD3100): A Phase I/II Study of AMD3100+MEC in Patients with Relapsed or Refractory Disease. (2008) (14)
- Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia (2022) (14)
- Cardiomyopathy in patients after posttransplant cyclophosphamide–based hematopoietic cell transplantation (2017) (14)
- Propensity Score Analysis of Conditioning Intensity in Peripheral Blood Haploidentical Hematopoietic Cell Transplantation. (2018) (14)
- Targeting bone marrow lymphoid niches in acute lymphoblastic leukemia. (2015) (14)
- A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplantation to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network Study 1102 (2020) (14)
- A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML (2013) (14)
- Shared cell of origin in a patient with Erdheim-Chester disease and acute myeloid leukemia (2019) (13)
- HLA epitope mismatch in haploidentical transplantation is associated with decreased relapse and delayed engraftment. (2018) (13)
- Factors Associated With Clinical Deterioration Among Patients Hospitalized on the Wards at a Tertiary Cancer Hospital. (2019) (13)
- Cellular immune therapy for refractory cancers: novel therapeutic strategies. (2005) (12)
- NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022. (2022) (12)
- A study of high-dose lenalidomide induction and low-dose lenalidomide maintenance therapy for patients with hypomethylating agent refractory myelodysplastic syndrome (2016) (12)
- Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia (2019) (12)
- HIV-1 V3 envelope sequences required for macrophage infection. (1995) (11)
- Hematologic Recovery after Pretransplant Chemotherapy Does Not Influence Survival after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients. (2015) (11)
- Peritransplant Serum Albumin Decline Predicts Subsequent Severe Acute Graft-versus-Host Disease after Mucotoxic Myeloablative Conditioning. (2016) (10)
- A Phase I/II Study of Chemosensitization with the CXCR4 Antagonist Plerixafor in Relapsed or Refractory AML. (2009) (10)
- Proteomic and phosphoproteomic landscapes of acute myeloid leukemia (2022) (10)
- Bone Marrow Biopsy Needle Type Affects Core Biopsy Specimen Length and Quality and Aspirate Hemodilution (2018) (9)
- Focal disruption of DNA methylation dynamics at enhancers in IDH-mutant AML cells (2021) (9)
- Selinexor in Combination with Cladribine, Cytarabine and G-CSF for Relapsed or Refractory AML (2017) (9)
- Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2x2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) (2018) (9)
- Phase I study of oral clofarabine consolidation in adults aged 60 and older with acute myeloid leukemia (2011) (9)
- A randomized phase II trial of CX-01 with standard therapy in elderly patients with acute myeloid leukemia (AML). (2019) (9)
- Formation of noninfectious HIV-1 virus particles lacking a full-length envelope protein. (1991) (8)
- Immunosuppression and outcomes in adult patients with de novo acute myeloid leukemia with normal karyotypes (2021) (8)
- Addition of Sorafenib to Chemotherapy Improves the Overall Survival of Older Adults with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) (Alliance C11001) (2015) (8)
- Lack of a Prognostic Impact of the MyD88 L265P Mutation for Diffuse Large B Cell Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. (2017) (8)
- A phase II study of V-BEAM as conditioning regimen before second auto-SCT for multiple myeloma (2014) (8)
- Myelodysplastic SyndromesPractice Guidelines in Oncology (2011) (8)
- Phase II Study of High Dose Lenalidomide as Initial Treatment for Older Acute Myeloid Leukemia Patients: Early Results Show a Significant Reduction of Bone Marrow Blasts after 14 Days of Therapy. (2007) (8)
- Phase I Study of Panobinostat Plus Decitabine In Elderly Patients with Advanced MDS or AML. (2010) (8)
- A Multi-Center, Randomized, Double Blind, Phase III Clinical Trial Comparing Steroids/Placebo Vs. Steroids/Mycophenolate Mofetil As Initial Therapy for Acute Graft-Versus-Host Disease. Blood and Marrow Transplant Clinical Trials Network Study 0802 (2013) (7)
- Pharmacokinetic Study of Infusional Valspodar (2002) (7)
- Updated Study Results of CX-01, an Inhibitor of CXCL12/CXCR4, and Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDS (2019) (7)
- A Phase I Study of the Safety and Feasibility of Bortezomib in Combination With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma. (2016) (7)
- S877 SAFETY AND CLINICAL ACTIVITY OF AMV564, A CD33/CD3 T-CELL ENGAGER, IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML): UPDATED RESULTS FROM THE PHASE 1 FIRST-IN-HUMAN TRIAL (2019) (7)
- A Phase II Study Of V-BEAM (Bortezomib, Carmustine, Etoposide, Cytarabine, and Melphalan) As Conditioning Regimen Prior To Second Autologous Stem Cell Transplantation For Multiple Myeloma (2013) (6)
- Use of Post-Transplant Cyclophosphamide (PTCy) with Mycophenolate Mofetil and Tacrolimus in HLA Matched Allogeneic Hematopoietic Cell Transplant Is Safe and Associated with Acceptable Transplant Outcomes (2015) (6)
- A Phase II Study of High Dose Lenalidomide as Initial Therapy for Acute Myeloid Leukemia in Patients > 60 Years Old. (2009) (6)
- Secondary acute lymphoblastic leukemia, a retrospective analysis from Washington University and meta-analysis of published data. (2018) (5)
- Myelodysplastic syndromes. (2011) (5)
- Transfer of the Multidrug Resistance Gene, MDR-1, to Hematopoietic Progenitors from a Patient with Transformed Large Cell Lymphoma, and Demonstration of In Vivo Chemotherapy Protection with Dose Escalating Chemotherapy. (2004) (5)
- Experience With CMX001, a Novel Antiviral Drug, for Cytomegalovirus infections in Stem Cell Transplant Patients (2011) (5)
- Impact of a 40-Gene Targeted Panel Test on Physician Decision Making for Patients With Acute Myeloid Leukemia (2021) (5)
- The Role of Allogeneic Transplant for Adult Ph+ ALL in CR1 with Complete Molecular Remission: A Retrospective Analysis. (2022) (5)
- Donor-Derived Smoldering Multiple Myeloma following a Hematopoietic Cell Transplantation for AML (2017) (5)
- Rapid and sustained response to immune checkpoint inhibition in cutaneous squamous cell carcinoma after allogenic hematopoietic cell transplant for sézary syndrome (2019) (5)
- Targeted Sequencing Informs the Evaluation of Normal Karyotype Cytopenic Patients for Low-Grade Myelodysplastic Syndrome (2016) (5)
- Clinical response of myelodysplastic syndromes patients to treatment with coenzyme Q10. (2007) (5)
- Phase I/II Study of Intravenous Plerixafor Added to a Mobilization Regimen of Granulocyte Colony-Stimulating Factor in Lymphoma Patients Undergoing Autologous Stem Cell Collection. (2017) (5)
- A Pilot Study of CPX-351 (Vyxeos ©) for Transplant Eligible, Higher Risk Patients with Myelodysplastic Syndrome (2021) (5)
- Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial. (2022) (4)
- Letermovir discontinuation at D+100 after Allogeneic Stem Cell Transplant is associated with increased CMV-related mortality. (2022) (4)
- The Activity and Toxicity of Dasatinib in Relapsed or Plateau-Phase Multiple Myeloma. (2007) (4)
- Kinetics of Autologous Stem Cell Mobilization Failure: Comparison of AMD3100/G-CSF, G-CSF, GM-/G-CSF, and Chemotherapy/G-CSF on Remobilization Success. (2006) (4)
- Do adults aged 70 years or older with acute myeloid leukemia benefit from allogeneic hematopoietic cell transplantation? (2016) (4)
- Combination of dociparstat sodium (DSTAT), a CXCL12/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS. (2021) (3)
- Myeloid growth factors. (2011) (3)
- Low dose Vidaza and thalidomide is an effective combination for patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). (2006) (3)
- The Predicted Indirectly Recognizable HLA Epitopes (PIRCHE) Score for HLA Class I Graft-Versus-Host Disparity Is Associated with Increased Acute Graft-Versus-Host Disease in Haploidentical Transplantation with Post-Transplant Cyclophosphamide. (2020) (3)
- Cytomegalovirus Viremia and Relapse after Haploidentical Hematopoietic Cell Transplantation (2016) (3)
- Single institution experience with G-CSF mobilized T-cell replete haploidentical hematopoietic cell transplantation (2016) (3)
- Maintenance Therapy With Decitabine After Allogeneic Hematopoietic Stem Cell Transplantation For Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome (2013) (3)
- The impact of CD34+ cell dose and comorbidities on engraftment following autologous hematopoietic stem cell transplantation (ASCT). (2014) (3)
- High Dose Sargramostim (GM-CSF) Combined with IV Plerixafor for the Mobilization of Peripheral Blood Stem Cells (PBSC) From Normal HLA-Matched Allogeneic Sibling Donors Results in Hypercoagulability (2012) (3)
- Allogeneic Hematopoietic Stem Cell Transplant Versus No Transplant in Adult Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in First Complete Remission and Complete Molecular Remission (2020) (3)
- Genetic and Transcriptional Contributions to Relapse in Normal Karyotype Acute Myeloid Leukemia (2021) (3)
- 5 Year Results of BMT CTN 0201: Unrelated Donor Bone Marrow Is Associated with Better Psychological Well-Being and Less Burdensome Chronic Gvhd Symptoms Than Peripheral Blood (2015) (3)
- CX-01, an inhibitor of CXCL12/CXCR4 axis and of platelet factor 4 (PF4), with azacitidine (AZA) in patients with hypomethylating agent (HMA) refractory AML and MDS. (2018) (3)
- Blinatumomab Consolidation Post Autologous Hematopoietic Stem Cell Transplantation in Patients with Diffuse Large B Cell Lymphoma (2020) (3)
- Increased Early Mortality after Fludarabine and Melphalan Conditioning with Peripheral Blood Grafts in Haploidentical SCT with Post-Transplant Cyclophosphamide (2019) (2)
- A Phase I Study Of Azacitidine After Donor Lymphocyte Infusion For Relapsed Acute Myeloid Leukemia Post Allogeneic Stem Cell Transplantation (2013) (2)
- Acute myeloid leukemia presenting with extensive bone marrow necrosis, leukemia cutis and testicular involvement: successful treatment with allogeneic hematopoietic stem cell transplantation (2016) (2)
- HLA disparity is not inconsequential in peripheral blood T-replete haploidentical hematopoietic stem cell transplantation (2016) (2)
- Phase I/II Study of Intravenous Plerixafor Added to a Mobilization Regimen of G-CSF in Lymphoma Patients Undergoing Autologous Stem Cell Collection (2012) (2)
- Post-Transplant Outcomes in AML Patients ≥ 60 Years of Age Beyond CR1 (2016) (2)
- Predicting Autologous Stem Cell Mobilization Failure In Hematologic Malignancies (2013) (2)
- Preliminary results of a phase II study of high dose lenalidomide as initial therapy for acute myeloid leukemia in patients ≥ 60 years old (2008) (2)
- A Phase I/II Trial of Intravenous Azacitidine for Acute Gvhd Prophylaxis in Patients Undergoing Matched Unrelated Stem Cell Transplantation: Phase I Results (2015) (2)
- Convergent Clonal Evolution of Signaling Gene Mutations Is a Hallmark of Myelodysplastic Syndrome Progression. (2022) (2)
- A phase I trial evaluating the effects of plerixafor, G-CSF, and azacitidine for the treatment of myelodysplastic syndromes (2021) (2)
- Complete Sequencing and Comparison of 12 Normal Karyotype M1 AML Genomes with 12 t(15;17) Positive M3-APL Genomes (2011) (2)
- Myeloid Growth FactorsPractice Guidelines in Oncology (2011) (2)
- Subclonal Evolution Characterizes MDS Disease Progression Following Allogeneic Stem Cell Transplant (2017) (2)
- A Phase 1 Study of Concomitant High Dose Lenalidomide and 5-Azacytidine Induction in the Treatment of Acute Myeloid Leukemia, (2011) (2)
- Ruxolitinib for steroid‐refractory acute graft‐versus‐host disease (2019) (1)
- Can molecular profiling of cytogenetic subgroups draw a roadmap for individualizing therapy in myelodysplastic syndromes? (2006) (1)
- Phase I Study of Intravenous Plerixafor Added to a Mobilization Regimen of G-CSF In Lymphoma Patients Undergoing Autologous Stem Cell Collection (2010) (1)
- Abstract 5704: Mass cytometry identifies the expansion, persistence, and immune checkpoints of adoptively transferred memory-like NK cells in patients with leukemia (2018) (1)
- A phase II, multicenter, randomized, double-blind, placebo-controlled trial of the safety and efficacy of velafermin (CG53135-05) administered intravenously as a single dose for the prevention of oral mucositis in patients receiving autologous hematopoietic stem cell transplant (AHSCT) (2006) (1)
- Plasma Vincristine Levels Are 100-Fold Higher with Marqibo® (Vincristine Sulfate LIPOSOME Injection) in Place of Standard Vincristine in Combination Chemotherapy of Patients ≥ 60 Years Old with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) (2015) (1)
- Whole Genome Sequencing of Therapy-Related Acute Myeloid Leukemia (2012) (1)
- 16: Kinetics of autologous stem cell mobilization failure (2007) (1)
- Acute Myeloid Leukemia Patients with Pre-Transplant Ablated Marrows Have Similar Rates of Survival and Relapse Compared to Patients in Complete Remission after Allogeneic Hematopoietic Cell Transplantation (2014) (1)
- Azacitidine-Induced Changes in the MDS Methylome Are Associated with Clinical Responses (2008) (1)
- A Phase II Study of Intravenous Azacitidine Alone in Patients with Myelodysplastic Syndromes NCT00384956. (2007) (1)
- Chemotherapy Versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome Following Allogeneic Stem Cell Transplant: A Retrospective Review (2014) (1)
- Association BetweenMutation Clearance After Induction Therapy andOutcomes in AcuteMyeloid Leukemia (2015) (1)
- Decitabine salvage for TP53-mutated, relapsed/refractory acute myeloid leukemia after cytotoxic induction therapy (2022) (1)
- Dynamic Changes in Clonal Clearance with Decitabine Therapy in AML and MDS Patients (2015) (1)
- Sequencing an Acute Myeloid Leukemia (AML) Genome with “Next Generation” Technologies. (2007) (1)
- Decitabine for Older AML Patients: An Effective Therapy Associated with Short Hospitalization and No Invasive Fungal Infection. (2010) (1)
- Haploidentical Peripheral Blood Stem Cell Transplantation Using Non-Myeloablative Conditioning With Post-Transplant Cyclophosphamide Regimen Is Safe and Is Associated With Very Encouraging Post-Transplant Outcomes (2013) (1)
- FLAG-IM (Fludarabine, Ara-C, G-CSF, Idarubicin, Mylotarg) Is an Effective Salvage Regimen Producing High Rates of Remission (CR+CRi) in Relapsed/Refractory AML. (2007) (1)
- Donor-to-Recipient Weight Ratio Is Independently Associated with CD34+ Yield in Healthy Donors Undergoing Peripheral Blood Stem Cell Collection for Allogeneic Transplantation (2014) (1)
- Impact of Disease and Mobilizing Agents on Initial and Remobilization Failure. (2006) (1)
- DNMT3A-Dependent DNA Methylation May Act As a Tumor Suppressor-Not a Tumor Promoter-during AML Progression (2016) (1)
- Prognostic Significance of PET Imaging in Relapsed or Refractory Classical Hodgkin Lymphoma Treated with Salvage Chemotherapy and Autologous Stem Cell Transplantation. (2009) (1)
- Low incidence of JAK2 and FLT3 mutations in patients with chronic myelomonocytic leukemia (CMML) (2006) (1)
- Tolerability of PTK787/ZK 222584 in a Phase II Study of Post-Transplant Maintenance Therapy in Patients with Multiple Myeloma Following High-Dose Chemotherapy and Autologous Stem Cell Transplant. (2007) (1)
- Phase I Study of Cladribine (2-chlorodeoxyadenosie), Cytarabine and G-CSF Based Induction Therapy (CLAG) with ATRA (All-trans retinoic acid) and Midostaurin for Relapsed/Refractory AML, (2011) (1)
- Protective effect of CMV reactivation on relapse after allogeneic hematopoietic cell transplantation in AML patients is influenced by their conditioning regimen Blood Marrow (2014) (1)
- A phase II study of intravenous azacitidine alone in patients with myelodysplastic syndromes: NCT0038495 (2008) (1)
- Reduced Intensity Hematopoietic Cell Transplantation in Active Disease AML Is Associated with Leukemia Free Survival and Relapse Comparable to Myeloablative Conditioning (2016) (1)
- T-cell replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide results in outcomes similar to traditionally matched donors in active disease acute myeloid leukemia (2017) (1)
- CD34+-Selected Infusions of Fresh or Cryopreserved Peripheral Blood Stem Cells for the Treatment of Poor Graft Function Following Allogeneic Hematopoietic Stem Cell Transplant (2015) (1)
- Salvage Therapy with Flag/Idarubicin/Mylotarg (Flag-IM) Results in a Superior CR/CRp Rate and Low Toxicity When Compared to Mitoxantrone/Etoposide/Cytarabine (MEC) in Patients with Relapsed and Refractory AML. (2006) (1)
- Lenalidomide results in a durable complete remission in acute myeloid leukemia accompanied by persistence of somatic mutations and a T-cell infiltrate in the bone marrow (2018) (1)
- Detection of Novel Mutations In MDS/AML by Whole Genome Sequencing (2010) (1)
- Downregulation of MHC Class II in Relapsed AML Cells after Allogeneic Transplantation (2017) (1)
- NCCN Myeloid Growth Factors Clinical Practice Guidelines in Oncology (2011) (1)
- Preliminary Data from a Multi-Center Study of Clofarabine / Busulfan Conditioning for Acute Myeloid Leukemia Not in Remission at Allogeneic Transplantation (2014) (1)
- Ruxolitinib for Steroid-Refractory Acute Graft-Versus-Host Diseas (2019) (1)
- Infectious Complications after Peripheral Blood (PB) Haploidentical Hematopoietic Cell Transplantation (haplo-HCT) (2016) (1)
- Mutations In the DNA Methyltransferase Gene DNMT3A Are Highly Recurrent In Patients with Intermediate Risk Acute Myeloid Leukemia, and Predict Poor Outcomes (2010) (1)
- Targeting Bone Marrow Lymphoid Niches In Acute Lymphoblastic Leukemia (2013) (0)
- Phase I Study of Brentuximab Vedotin for the Prevention of Acute GvHD after Unrelated Allogeneic Stem Cell Transplantation (2016) (0)
- CORONARY ARTERY BYPASS GRAFTING IN HIGH-RISK MYELODYSPLASTIC SYNDROME (2019) (0)
- ABO Mismatch Status Does Not Influence the Clinical Outcomes in Haploidentical Hematopoeitic Cell Transplantation (2016) (0)
- Cellular Stressors Contribute to the Expansion of Multiple Hematopoietic Clones of Varying Leukemic Potential (2017) (0)
- The Role of Transplant Conditioning Regimen Intensity in High-Risk AML. (2019) (0)
- The effect of donor type on outcomes in adults with acute myeloid leukemia after reduced‐intensity hematopoietic peripheral blood cell transplant – a retrospective study (2020) (0)
- Sargramostim (GM-CSF) Combined with IV Plerixafor to Mobilize Peripheral Blood Stem Cells (PBSC) from Normal HLA-Matched Allogeneic Sibling Donors (2014) (0)
- Comparison of Deep Learning, Machine Learning, and Penalized Logistic Regression for Predicting Clinical Deterioration in Oncology Inpatients (2020) (0)
- Abstract PR11: Genomic approaches for risk assessment in acute myeloid leukemia (2015) (0)
- 17: Impact of disease and mobilizing agents on initial and remobilization failure (2007) (0)
- Impact of Anti- T Lymphocyte Globulin (ATLG) on Immune Reconstitution in Patients Undergoing HLA Matched Unrelated Myeloablative Hematopoietic Cell Transplantation (HCT): Results From a Prospective Randomized Double Blind Phase 3 Clinical Trial (2017) (0)
- Hematologic Recovery Following Pre-Transplant Chemotherapy Does Not Influence Survival after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients (2016) (0)
- Ex Vivo Pharmacologic Modulation in a Nutrient-Rich Medium to Accelerate Engraftment of Human Umbilical Cord Blood (2014) (0)
- Busulfan/Fludarabine/Thymoglobulin as a Reduced Intensity Conditioning Regimen for Lymphoid Malignancies. (2009) (0)
- Risk Factors for the Development of and Outcomes of Patients Who Develop Severe Cytokine Release Syndrome after Peripheral Blood Haploidentical Donor Transplant (2016) (0)
- Signaling Gene Mutations Are Characterized By Diverse Patterns of Expansion and Contraction during Progression from MDS to Secondary AML (2020) (0)
- Outcomes after Second Allogeneic Hematopoietic Cell Transplantation in Adults with Hematologic Malignancies (2017) (0)
- Next-Generation Sequencing: A Discovery Tool for Blood Disorders (2012) (0)
- Comparable Survival with HLA Haploidentical and Mismatched Unrelated Donor Transplants in Patients with AML and MDS (2016) (0)
- Dynamic Changes in MDS Clonal Architecture Following Allogeneic Stem Cell Transplant (2016) (0)
- Genome-wide analysis of focal DNA hypermethylation in IDH-mutant AML samples (2021) (0)
- Clinical Characteristics of Isolated CNS Relapse after Allogeneic Transplantation for AML — Poor Outcomes Despite Longer Time to Relapse (2017) (0)
- The Use of CD34 + -Selected Stem Cell Boosts Following HLA-Haploidentical Hematopoietic Cell Transplantation (2016) (0)
- T-Cell Replete Peripheral Blood Haploidentical Donor Transplant Is Frequently Associated with Cytokine Release Syndrome Which Responds to Anti-IL-6 Therapy (2015) (0)
- Pre-Conditioning Minus Nadir Serum Albumin in the First Two Weeks after Myeloablative Allogeneic Hematopoietic Cell Transplantation Predicts Subsequent Severe Acute Graft-Versus-Host-Disease (2016) (0)
- plerixafor in relapsed or refractory acute myeloid leukemia A phase I/II study of chemosensitization with the CXCR4 antagonist (2012) (0)
- Mgta-117, an Anti-CD117-Amanitin Antibody-Drug Conjugate, in Participants with Relapsed/Refractory Adult Acute Myeloid Leukemia (AML) and Myelodysplasia with Excess Blasts (MDS-EB): Safety, Pharmacokinetics, and Pharmacodynamics Initial Findings from a Phase 1/2 Study (2023) (0)
- Non-Malignant Oligoclonal Hematopoiesis Commonly Follows Cytoreductive Chemotherapy in Adult De Novo AML Patients (2015) (0)
- Favorable Outcomes with Acceptable Toxicity Using a Reduced Intensity Conditioning Regimen for Patients Otherwise Ineligible for Related Donor Allogeneic Stem Cell Transplantation. (2004) (0)
- Role of Transplant Conditioning Regimen Intensity in High-Risk Acute Myelogenous Leukemia (2020) (0)
- SARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: a prospective, multicentre, observational study (2023) (0)
- Clonal Evolution of Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation (2016) (0)
- HLA Epitope Mismatch in T Cell-Replete Haploidentical Hematopoietic Cell Transplantation is Associated with Worse Relapse Free Survival and Longer Engraftment (2018) (0)
- Plerixafor, G-CSF and Azacitidine For The Treatment Of MDS: Results Of a Phase I Trial (2013) (0)
- In Vivo Chemotherapy Protection and Efficacy of Multidrug Resistance (MDR-1) Gene Transfer in a Patient with Refractory Non-Hodgkin’s Lymphoma (NHL). (2005) (0)
- Resolution of a Clinical Dilemma with Whole Genome Sequencing, and Discovery of a New Mechanism for Generating PML-Rara: Insertional Fusion (2010) (0)
- Whole-Genome Sequencing and Acute Promyelocytic Leukemia—Reply (2011) (0)
- Expression of Proliferation Related Genes in Myelodysplastic Syndromes (MDS) and Secondary Acute Myeloid Leukemia (AML) Patients with Resistance to Low Dose Vidaza and Thalidomide. (2006) (0)
- Outcomes after second allogeneic hematopoietic stem cell transplantation: A single-center experience. (2014) (0)
- A Study of High Dose Lenalidomide Induction and Low Dose Lenalidomide Maintenance for Patients with Hypomethylating Agent Refractory MDS (2014) (0)
- T-Cell-Replete Haploidentical Transplantation Using Post-Transplant Cyclophosphamide in Active Disease AML and MDS Leads to Outcomes Similar to Matched Related and Unrelated Donor Transplantation (2016) (0)
- Survival After Second Allogeneic Transplant Is Improved in Recipients by Using the Original Donor (2013) (0)
- Immunosuppression and Outcomes in Acute Myeloid Leukemia (2021) (0)
- T-Cell Replete Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide Results in Outcomes Similar to Those of Traditionally Matched Donors in Active Acute Myeloid Leukemia (2017) (0)
- Busulfan-Based Reduced Intensity Conditioning Regimen (RIC) For Lymphoid Malignancies (2010) (0)
- Tandem Autologous/Non-Myeloablative Allogeneic Transplantation for High Risk Non-Hodgkin Lymphoma (NHL) (2018) (0)
- Booster Infusion of T-Cell Depleted, CD34+ Enriched, Donor Cells Results in Sustained Count Recovery for Patients with Poor Graft Function Following Allogeneic Stem Cell Transplantation (2012) (0)
- Abstract LB-109: Exome sequencing identifies common somatic mutations in an adult patient with a concurrent germ cell tumor (GCT) and acute myeloid leukemia (AML) suggesting a single clonal origin (2015) (0)
- Use of Belimumab for Prophylaxis of Chronic Graft-Versus-Host Disease (2021) (0)
- Clinician Perspectives on Barriers and Enablers to Implementing an Inpatient Oncology Early Warning System: A Mixed-Methods Study. (2023) (0)
- Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential (2018) (0)
- A Single-Arm, Open-Label, Pilot Study of the JAK1 Selective Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome in T-Cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation (2021) (0)
- Absolute Lymphocyte Count Recovery Predicts Post Transplant Outcomes in Peripheral Blood Haploidentical Transplantation (2016) (0)
- Mgta-117, an Anti-CD117 Antibody-Drug Conjugated with Amanitin, in Participants with Relapsed/Refractory Adult Acute Myeloid Leukemia (AML) and Myelodysplasia with Excess Blasts (MDS-EB): Safety, Pharmacokinetics and Pharmacodynamics Initial Findings from a Phase 1/2 Study (2022) (0)
- Exome analysis of treatment‐related AML after APL suggests secondary evolution (2018) (0)
- Mutation Analysis in Patients with High-Risk Myelodysplastic Syndrome Receiving Allogeneic Hematopoietic Cell Transplantation Based on Biological Donor Availability: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Study 1102 (2022) (0)
- Praveen – “ Proteome-wide binding site network analysis of M . tuberculosis ” ( Panel ) (2011) (0)
- The Molecular Basis of Long First Remissions in Normal Karyotype AML Patients (2019) (0)
- Humoral Immunogenicity of Sars-Cov-2 Vaccination in the First Year after Hematopoietic Cell Transplant or Chimeric Antigen Receptor T Cell Therapy: A CIBMTR and BMT CTN Study (2022) (0)
- 381: Sildenafil (Revatio) Therapy in Chronic Graft Versus Host Disease (cGVHD): Improvement in Pulmonary cGVHD Symptoms (2008) (0)
- arising in the setting of severe congenital neutropenia Distinct patterns of mutations occurring in de novo AML versus AML (2013) (0)
- expression α very low levels of PML-RAR High-penetrance mouse model of acute promyelocytic leukemia with (2013) (0)
- using plerixafor, an antagonist of the CXCR4/SDF-1 interaction Rapid mobilization of functional donor hematopoietic cells without G-CSF (2011) (0)
- Graft Lymphocyte Content Does Not Influence Outcomes after Peripheral Blood Haploidentical Transplants Using Post Transplant Cyclophosphamide (PTCy) (2016) (0)
- Sildenafil (REVATIO) Therapy In Chronic Graft Versus Host Disease (cGVHD): Continued Improvement In Pulmonary cGVHD Symptoms (2009) (0)
- Genomic landscape of TP53-mutated myeloid malignancies (2023) (0)
- The effect of donor source on outcomes after second allogeneic hematopoietic cell transplantation for relapsed leukemia. (2017) (0)
- IFNL4 and donor selection for matched unrelated donor haematopoietic stem-cell transplantation (2020) (0)
- High Resolution Array-Based CGH and SNP Studies of AML Genomes. (2007) (0)
- Addition of Mycophenolate Mofetil to Methotrexate and Tacrolimus Does Not Improve Gvhd Outcomes in Reduced Intensity Allogeneic Hematopoietic Cell Transplantation (2015) (0)
- Improving Risk Assessment of AML with a Precision Genomic Strategy to Assess Mutation Clearance (2018) (0)
- Prophylactic infusions of granulocytes do not increase the risk of CMV viremia post allogeneic peripheral blood stem cell transplantation (ALLO-PBSCT) (2000) (0)
- result in an unstable predictive model. How highly corre- lated are these variables, and what might be the impact on generalizability? (2016) (0)
- Evidence for Complete Mutation Clearance in Normal Karyotype AML Patients with Very Long (> 5 years) Remissions after Chemotherapy Alone (2018) (0)
- T-Cell Replete Peripheral Blood Stem Cell Transplantation after Non-Myeloablative Conditioning with Post-Transplant High Dose Cyclophosphamide Is Safe and Is Associated with Acceptable Outcomes (2014) (0)
- A Phase II Trial of Combination Therapy with Thalidomide, Arsenic Trioxide, Dexamethasone, and Ascorbic Acid (TADA) in Patients with Chronic Idiopathic Myelofibrosis (CIMF) or Overlap Myelodysplastic/Myeloproliferative Diseases (MDS/MPD). (2006) (0)
- High Calculated Glomerular Filtration Rate is Associated with Treatment-Related Mortality in Older Adults Undergoing Allogeneic Hematopoietic Cell Transplantation (2018) (0)
- Abstract PR03: Genomic approaches for risk assessment in acute myeloid leukemia (2015) (0)
- Analysis of the Proteomes of Primary, De Novo Acute Myeloid Leukemia Cells from Adults (2021) (0)
- First-in-Human Clinical Trial of the IL-15 Super-Agonist Complex ALT-803 for Patients Relapsed after Allogeneic Hematopoietic Cell Transplantation (2017) (0)
- Efficacy of Desensitization Therapy for Donor-Specific Anti-HLA Antibodies in Patients Undergoing Haploidentical Hematopoietic Cell Transplant (2018) (0)
- Phase II Study Evaluating the Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem and Progenitor Cells for Allogeneic Hematopoietic Cell Transplantation and Phenotypic Characterization of the Leukapheresis Product (2018) (0)
- Haploidentical Transplant with Peripheral Blood Hematopoietic Cell Grafts in Older Adults with AML or MDS (2016) (0)
- Transplant Outcomes in Older Patients Are Comparable to Outcomes in Younger Patients after Hopkin's Non-Myeloablative Flu Cy TBI + PT-Cy Regimen (2015) (0)
- Allogeneic hematopoietic cell transplantation in morphologic leukemia‐free aplastic state (2017) (0)
- Allogeneic Stem Cell Transplantation Conditioning for MDS and AML with Clofarabine, Cytarabine and ATG (2008) (0)
- Remobilization with G-CSF Is Less Effective Than the Initial Mobilization in Healthy Donors Undergoing Peripheral Blood Stem Cell Collection for Allogeneic Transplantation (2014) (0)
- Impact of Remission Status on Outcomes in AML Patients ≥ 60 Years of Age after Allogeneic Stem Cell Transplantation (2014) (0)
- Phase I Study of Baricitinib Gvhd Prophylaxis in HLA-Matched, Peripheral Blood Allogeneic Hematopoietic Cell Transplant (2022) (0)
- A Single-Institution Randomized Prospective Trial of Pre-Emptive Therapy with Oral Valganciclovir Compared with IV Ganciclovir for Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplant (aHSCT), Delayed until Viral Load (VL) >10,000 Copies/Ml or >5,000 Copies/Ml X 2 (2008) (0)
- Prognostic Significance of Minimal Residual Disease in Patients with Secondary Acute Myeloid Leukemia (2017) (0)
- A Retrospective Review of Response to Donor Leukocyte Infusions In Adults with Acute Myeloid Leukemia After Reduced Intensity Conditioned Allogeneic Hematopoietic Cell Transplantation. (2010) (0)
- Adverse Outcomes in Acute Myeloid Leukemia Are Associated with Tumor Cell-Mediated Immunosuppression (2021) (0)
- Abstract 4342: Predictive precision medicine platform accurately predicts individual patient response to AML treatments to maximize outcomes (2023) (0)
- Erratum: Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia (Cancer (2013) 119 (90-8)) (2014) (0)
This paper list is powered by the following services:
Other Resources About Peter Westervelt
What Schools Are Affiliated With Peter Westervelt?
Peter Westervelt is affiliated with the following schools:
